ZymoGenetics

Home | Contact Us | Sitemap

  • Stock Quote
  • ZGEN:NASDAQ GM
  • Last: $4.50
  • Volume: 146,695
  • As of Jul 2, 2009 ET
  • Minimum 20 minutes delayed
THERAPEUTIC AREAS
  • Hepatitis C
    • PEG-Interferon lambda
  • Immunology
    • IL-21 mAb
    • IL-31 mAb
    • FcγR1a
  • Oncology
    • IL-21
  • Surgical Bleeding
NEWS
  • Jun 10, 2009 - ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
  • May 31, 2009 - ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar(R)
  • May 14, 2009 - Final Phase 2 Results for IL-21 in Renal Cell Cancer Show Tolerability and Enhanced Efficacy of Nexavar Combination
  • News Archive »
EVENTS
  • Replay
    ZymoGenetics Inc. at Bank of America Securities Healthcare Conference
    May 13, 2009 at 10:40 a.m. ET
  • Replay
    ZymoGenetics First Quarter 2009 Financial Results
    May 5, 2009, 4:30 p.m. ET
  • Events Archive »
CORPORATE RESOURCES
  • 2008 Annual Report
  • Full Year 2008
  • 1st Quarter 2009


© ZymoGenetics Inc., Terms & Conditions